These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23021089)

  • 21. Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression.
    Maffezzini M; Campodonico F; Canepa G; Manuputty EE; Tamagno S; Puntoni M
    Cancer Chemother Pharmacol; 2014 May; 73(5):925-30. PubMed ID: 24585046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
    Moschini M; Salonia A; Briganti A; Montorsi F
    Eur Urol; 2023 Oct; 84(4):439-440. PubMed ID: 36967362
    [No Abstract]   [Full Text] [Related]  

  • 23. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
    Mostafid AH; Rajkumar RG; Stewart AB; Singh R
    BJU Int; 2006 Mar; 97(3):509-12. PubMed ID: 16469017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup.
    Solsona E; Iborra I; Ricós JV; Monrós JL; Casanova J; Dumont R
    J Urol; 1999 Apr; 161(4):1120-3. PubMed ID: 10081851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Commentary on "economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases." Lee CT, Barocas D, Globe DR, Oefelein MG, Colayco DC, Bruno A, O׳Day K, Bramley T, Department of Urology, University of Michigan, Ann Arbor, MI.: J Urol 2012;188(6):2114-9. [Epub 2012 Oct 18]. doi: 10.1016/j.juro.2012.08.005.
    Hollenbeck BK
    Urol Oncol; 2014 Oct; 32(7):1089. PubMed ID: 25443143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. a pilot study on marker lesion.
    Colombo R; Brausi M; Da Pozzo L; Salonia A; Montorsi F; Scattoni V; Roscigno M; Rigatti P
    Eur Urol; 2001 Jan; 39(1):95-100. PubMed ID: 11173946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Intravesical therapy with mitomycin through electromotive drug administration].
    Verri C; Liberati E; Celestino F; De Carlo F; Torelli F; Di Stasi SM
    Urologia; 2013; 80(2):105-11. PubMed ID: 23852927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
    O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
    BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study.
    Geijsen ED; de Reijke TM; Koning CC; Zum Vörde Sive Vörding PJ; de la Rosette JJ; Rasch CR; van Os RM; Crezee J
    J Urol; 2015 Nov; 194(5):1202-8. PubMed ID: 26143111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
    Besarani D; Al-Akraa M
    BJU Int; 2006 Jul; 98(1):232-3. PubMed ID: 16831177
    [No Abstract]   [Full Text] [Related]  

  • 32. Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?
    Kiss B; Schneider S; Thalmann GN; Roth B
    Int J Urol; 2015 Feb; 22(2):158-62. PubMed ID: 25339291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Intravesical instillation for bladder tumors].
    Rivière A; Ploussard G; Desgranchamps F
    Rev Prat; 2014 Dec; 64(10):1388-9. PubMed ID: 25665319
    [No Abstract]   [Full Text] [Related]  

  • 34. Single instillation of mitomycin C reduces 1st year recurrence following transurethral resection of non-muscle invasive bladder cancer.
    Ather MH; Aziz S; Sulaiman MN
    J Ayub Med Coll Abbottabad; 2007; 19(4):18-20. PubMed ID: 18693589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study of the synergy of microwave hyperthermia/intravesical chemotherapy in the prevention of recurrences of superficial tumors of the bladder].
    Mauroy B; Bonnal JL; Prevost B; Chive M; Lhotellier V; Sozanski JP; Vanseymortier L; Stefaniak X
    Prog Urol; 1999 Feb; 9(1):69-80. PubMed ID: 10212955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.
    Halachmi S; Moskovitz B; Maffezzini M; Conti G; Verweij F; Kedar D; Sandri SD; Nativ O; Colombo R
    Urol Oncol; 2011; 29(3):259-64. PubMed ID: 19395285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer].
    Rouprêt M; Neuzillet Y; Larré S; Pignot G; Coloby P; Rébillard X; Mongiat-Artus P; Chartier-Kastler E; Soulié M; Pfister C;
    Prog Urol; 2012 Nov; 22(15):920-31. PubMed ID: 23102014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
    Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
    Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.
    Shapiro O; Jones K; Wang C; Landas S; Haas GP
    Can J Urol; 2006 Dec; 13(6):3317-20. PubMed ID: 17187694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
    Seo HK; Cho KS; Chung J; Joung JY; Park WS; Chung MK; Lee KH
    Urology; 2010 Aug; 76(2):512.e1-7. PubMed ID: 20579709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.